losartan has been researched along with Raynaud Disease in 6 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Raynaud Disease: An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most patients with systemic sclerosis (SSc) have Raynaud's phenomenon (RP), which is often more severe than idiopathic RP." | 2.41 | Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. ( Fenlon, D; Pope, JE; Shea, B; Thompson, AE; Welch, V, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Drobek, HH | 1 |
| Porwolik, M | 1 |
| Pietrauszka, K | 1 |
| Miziołek, B | 1 |
| Bergler-Czop, B | 1 |
| Brzezińska-Wcisło, L | 1 |
| Pancera, P | 1 |
| Sansone, S | 1 |
| Secchi, S | 1 |
| Covi, G | 1 |
| Lechi, A | 1 |
| Dziadzio, M | 1 |
| Denton, CP | 1 |
| Smith, R | 1 |
| Howell, K | 1 |
| Blann, A | 1 |
| Bowers, E | 1 |
| Black, CM | 1 |
| Lazareth, I | 1 |
| Thompson, AE | 1 |
| Shea, B | 1 |
| Welch, V | 1 |
| Fenlon, D | 1 |
| Pope, JE | 1 |
| Bridges, MJ | 1 |
| Kelly, CA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.[NCT03211325] | 29 participants (Actual) | Interventional | 2016-10-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for losartan and Raynaud Disease
| Article | Year |
|---|---|
What is the Best Way to Treat Patients with Raynaud's Phenomenon and a Tendency towards Hypotension?
Topics: Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypotension; Losartan; Nifedipine; Nitrog | 2020 |
[Management of Raynaud's phenomenon].
Topics: Adult; Age Distribution; Calcium Channel Blockers; Female; Humans; Iloprost; Losartan; Male; Middle | 2001 |
Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Topics: Calcium Channel Blockers; Cross-Over Studies; Humans; Iloprost; Injections, Intravenous; Ischemia; L | 2001 |
2 trials available for losartan and Raynaud Disease
| Article | Year |
|---|---|
The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon.
Topics: Adolescent; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood | 1997 |
Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Topics: Adult; Aged; Female; Humans; Losartan; Male; Middle Aged; Nifedipine; Pilot Projects; Raynaud Diseas | 1999 |
1 other study available for losartan and Raynaud Disease
| Article | Year |
|---|---|
Raynaud's phenomenon affecting the tongue of a patient with scleroderma.
Topics: Female; Humans; Losartan; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Tongue Diseases; Vaso | 2002 |